Retour aux projets

13265.1 PFLS-LS

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Résumé

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Textes supplémentaires

Abstract

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.

Participants

Liane Höfferer

Wirtschaftspartner

CSL Behring AG CHE-105.544.325 Liane Höfferer Wankdorfstrasse 10 3014 Bern BE CH

Dominik Schaer

Kontaktperson

dominik.schaer@usz.ch

USZ Universitätsspital Zürich Dominik Schaer Rämistrasse 100 8091 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2012-02-29
Date de fin
2015-12-31
Coûts totaux approuvés
CHF 1101000.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T115 Medical technology 100.0%